Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01475461 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 345
- Enrollment target
NCT01475461: Completed Phase 2 study, sponsored by Pfizer.
NCT01475461 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 345 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (159% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01475461, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 345 participants
- Enrollment target
Study Summary
B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes
Primary Outcome
HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than (\<) 6.5 percent (%) by the study-specific central laboratory used. Change from baseline in percentage of HbA1c in participants were reported.
Interventions
- DRUG Placebo
- DRUG PF-04937319 - 3mg
- DRUG PF-04937319 - 20mg
- DRUG PF-04937319 - 50mg
- DRUG PF-04937319 - 100mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
What the finished NCT01475461 record still lists
NCT01475461 is an interventional study that assigns participants to a tested intervention. The registered 345 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (159% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01475461 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01475461 about?
NCT01475461 is a clinical study titled "Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes". B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes
What is the current status of trial NCT01475461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 345 participants. The study started on 2011-11. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01475461?
The interventions under investigation include: Placebo (DRUG), PF-04937319 - 3mg (DRUG), PF-04937319 - 20mg (DRUG), PF-04937319 - 50mg (DRUG), PF-04937319 - 100mg (DRUG).
Who is sponsoring clinical trial NCT01475461?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01475461's enrollment target sits among peer trials
345 136th of 2000 higher than 1,865 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- NCT05107674 · 345 participants · Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
- NCT05700279 · 345 participants · NA
Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset
- NCT05781100 · 345 participants · NA
Investigating Baby Behavior and Family Technology Use Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia